'Fuzziness' in pharmacophore-based virtual screening and de novo design

Drug Discovery Today: Technologies

Volumn 7, Issue 4, 2010, Pages

  Klenner, Alexander ^a   Hartenfeller, Markus ^a   Schneider, Petra ^a   Schneider, Gisbert ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFORMATION; EXPERIMENTAL STUDY; FUZZY SYSTEM; MOLECULAR DYNAMICS; PHARMACOPHORE; SCREENING TEST; STRUCTURE ANALYSIS; VIRTUAL SCREENING;

EID: 78650756183     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2010.10.004     Document Type: Review

References (55)

1. A. Leach Three-dimensional pharmacophore methods in drug discovery J. Med. Chem. 53 2010 539 558
2. D. Horvath, and C. Jeandenans Neighborhood behavior of in silico structural spaces with respect to in vitro activity spaces - a benchmark for neighborhood behavior assessment of different in silico similarity metrics J. Chem. Inf. Comput. Sci. 43 2003 691 698
3. J. Polanski Self-organizing neural networks for pharmacophore mapping Adv. Drug Deliv. Rev. 55 2003 1149 1162
4. S. Renner, and G. Schneider Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening J. Med. Chem. 47 2004 4653 4664
5. G. Schneider 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening Angew. Chem. Int. Ed. Engl. 38 1999 2894 2896
6. G. Schneider Scaffold hopping: how far can you jump? QSAR Comb. Sci. 25 2006 1162 1171
7. S.R. Langdon Bioisosteric replacement and scaffold hopping in lead generation and optimization Mol. Inf. 29 2010 366 385
8. L.A. Zadeh Fuzzy sets Inform. Control. 8 1965 338 353
9. F. Bonachéra Fuzzy tricentric pharmacophore fingerprints. 1. Topological fuzzy pharmacophore triplets and adapted molecular similarity scoring schemes J. Chem. Inf. Model. 46 2006 2457 2477
10. B. Kosko, and S. Isaka Fuzzy logic Sci. Am. 269 1993 76 81
11. U. Fechner, and G. Schneider Optimization of a pharmacophore-based correlation vector descriptor for similarity searching QSAR Comb. Sci. 23 2004 19 22
12. M. Rella Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors J. Chem. Inf. Model. 46 2006 708 716
13. K. Moffat A comparison of field-based similarity searching methods: CatShape, FBSS, and ROCS J. Chem. Inf. Model. 48 2008 719 729
14. ROCS-CFF Openeye Scientific Software 2005
15. E. Proschak From molecular shape to potent bioactive agents. I: Bioisosteric replacement of molecular fragments ChemMedChem 4 2009 41 44
16. S.L. Dixon PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput. Aided Mol. Des. 20 2006 647 671
17. M. Baroni A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application J. Chem. Inf. Model. 47 2007 279 294
18. T. Kohonen Self-organizing formation of topologically correct feature maps Biol. Cybern. 43 1982 59 69
19. Y. Tanrikulu, and G. Schneider Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening Nat. Rev. Drug Discov. 7 2008 667 677
20. J. Sadowski Comparison of automatic three-dimensional model builders using 639 X-ray structures J. Chem. Inf. Comput. Sci. 34 1994 1000 1008
21. A. Klenner Automated docking of flexible molecules into receptor binding sites by ligand self-organization in situ Mol. Inf. 29 2010 189 193
22. H. Xu Conformational sampling by self-organization J. Chem. Inf. Comput. Sci. 43 2003 1186 1191
23. Y. Tanrikulu Scaffold hopping by 'fuzzy' pharmacophores and its application to RNA targets ChemBioChem 8 2007 1932 1936
24. A. Manning SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs J. Cardiovasc. Pharmacol. 25 1995 252 261
25. P. Schneider, and G. Schneider Collection of bioactive reference compounds for focused library design QSAR Comb. Sci. 22 2003 713 718
26. P. Labute Flexible alignment of small molecules J. Med. Chem. 44 2001 1483 1490
27. A.C. Good, and T.O. Oprea Optimization of CAMD techniques. 3. Virtual screening enrichment studies: a help or hindrance in tool selection? J. Comput. Aided Mol. Des. 22 2008 169 178
28. M.D. Mackey, and J.L. Melville Better than random? The chemotype enrichment problem J. Chem. Inf. Model. 49 2009 1154 1162
29. J. Kirchmair Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates Curr. Med. Chem. 15 2008 2040 2053
30. A. Kaiser The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase Arch. Biochem. Biophys. 386 2001 179 187
31. N.G. Oikonomakos Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site J. Biol. Chem. 275 2000 34566 34573
32. R. Nahta Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer Cancer Res. 63 2003 3626 3631
33. S. Kobayashi Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling Cancer Res. 66 2006 11389 11398
34. H.H. Sedlacek Mechanisms of action of flavopiridol Crit. Rev. Oncol. Hematol. 38 2001 139 170
35. N. Gao Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol Mol. Pharmacol. 66 2004 956 963
36. M.V. Blagosklonny Flavopiridol, an inhibitor of transcription Cell Cycle 3 2004 1537 1542
37. G. Schneider Selforganizing molecular fingerprints: a ligand-based view on druglike chemical space and off-target prediction Future Med. Chem. 1 2009 213 218
38. B.A. Krueger Scaffold-hopping potential of fragment-based de novo design: the chances and limits of variation Comb. Chem. High Throughput Screen. 12 2009 383 396
39. J. Degen, and M. Rarey FlexNovo: structure-based searching in large fragment spaces ChemMedChem 1 2006 854 868
40. M. Hartenfeller, and G. Schneider De novo drug design Methods Mol. Biol. 672 2010 299 323
41. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893
42. J.S. Sawyer Synthesis and activity of new aryl- and heteroaryl- substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain J. Med. Chem. 46 2003 3953 3956
43. R.L. Thurmond A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties J. Pharmacol. Exp. Ther. 309 2004 404 413
44. M. Rarey, and J.S. Dixon Feature trees: a new molecular similarity measure based on tree matching J. Comput. Aided Mol. Des. 12 1998 471 490
45. N. Stiefl ErG: 2D pharmacophore descriptions for scaffold hopping J. Chem. Inf. Model. 46 2006 208 220
46. E.J. Barker Further development of reduced graphs for identifying bioactive compounds J. Chem. Inf. Comput. Sci. 43 2003 346 356
47. E.J. Barker Scaffold hopping using clique detection applied to reduced graphs J. Chem. Inf. Model. 46 2006 503 511
48. K.J. Okolotowicz Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway Bioorg. Med. Chem. 18 2010 1918 1924
49. A.S. Kalgutkar Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators J. Med. Chem. 41 1998 4800 4818
50. M. Rupp Kernel approach to molecular similarity based on iterative graph similarity J. Chem. Inf. Model 47 2007 2280 2286
51. J.L. Jenkins A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes J. Med. Chem. 47 2004 6144 6159
52. O. Sperandio MED-SuMoLig: a new ligand-based screening tool for efficient scaffold hopping J. Chem. Inf. Model 47 2007 1097 1110
53. S.L. Kinnings, and R.M. Jackson LigMatch: a multiple structure-based ligand matching method for 3D virtual screening J. Chem. Inf. Model 49 2009 2056 2066
54. A. Jahn Probabilistic modeling of conformational space for 3D machine learning approaches Mol. Inf. 29 2010 441 445
55. Z.J. Zia 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs Bioorg. Med. Chem. Lett. 14 2004 1221 1227